Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026)
Ocular Therapeutix's (OCUL) quarterly Income from Continuing Operations came in at 90067000.0 in Q1 2026, down 42.79% year-on-year from 157441898.54 in Q1 2025, and down 33.5% quarter-over-quarter from 67467000.0 in Q4 2025.
Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 90067000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 42.79% year-over-year to 90067000.0 in Q1 2026; TTM through Mar 2026 was 292707000.0, a 49.03% decrease from a year earlier, with the FY2025 full-year figure at 544111000.0, down 44.42% from the prior year.
- Income from Continuing Operations declined to 90067000.0 in Q1 2026 per OCUL's latest filing, from 67467000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 16312000.0 in Q4 2022 and bottomed at 90067000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 40662000.0 (2024), against an average of 41425764.71.
- Across the five-year window, Income from Continuing Operations grew 17.29% in 2022 and plunged 103.33% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 16312000.0 in 2022, then sank by 65.91% to 27064000.0 in 2023, then tumbled by 81.09% to 49011000.0 in 2024, then slumped by 37.66% to 67467000.0 in 2025, then tumbled by 33.5% to 90067000.0 in 2026.
- Per Business Quant, the three latest OCUL Income from Continuing Operations figures stand at 90067000.0 (Q1 2026), 67467000.0 (Q4 2025), and 67971000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Ocular Therapeutix | 1.91 Bn | 1.91 Bn | 9.46 Mn | -90.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.07 Mn |
| Dec 31, 2025 | -67.47 Mn |
| Sep 30, 2025 | -67.97 Mn |
| Jun 30, 2025 | -67.20 Mn |
| Mar 31, 2025 | -63.08 Mn |
| Dec 31, 2024 | -49.01 Mn |
| Sep 30, 2024 | -43.57 Mn |
| Jun 30, 2024 | -40.75 Mn |
| Mar 31, 2024 | -40.66 Mn |
| Dec 31, 2023 | -27.06 Mn |
| Sep 30, 2023 | -21.43 Mn |
| Jun 30, 2023 | -21.81 Mn |
| Mar 31, 2023 | -23.75 Mn |
| Dec 31, 2022 | -16.31 Mn |
| Sep 30, 2022 | -23.06 Mn |
| Jun 30, 2022 | -21.54 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -21.18 Mn |
| Jun 30, 2021 | -21.88 Mn |